Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €1.96 EUR
Change Today -0.267 / -11.97%
Volume 500.0
XS5A On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 11:40 AM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

echo therapeutics inc (XS5A) Snapshot

Open
€1.98
Previous Close
€2.23
Day High
€2.06
Day Low
€1.88
52 Week High
03/16/15 - €2.75
52 Week Low
09/24/14 - €0.25
Market Cap
24.8M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
12.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ECHO THERAPEUTICS INC (XS5A)

Related News

No related news articles were found.

echo therapeutics inc (XS5A) Related Businessweek News

No Related Businessweek News Found

echo therapeutics inc (XS5A) Details

Echo Therapeutics, Inc. is engaged in the development of transdermal skin permeation and diagnostic medical devices. It is developing Symphony CGM system (Symphony), a needle-free wireless continuous glucose monitoring system for use in hospital critical care units; and Symphony SkinPrep system, a component of its Symphony for enhanced skin permeation that enables extraction of analytes, such as glucose. The company is also engaged in the development Durhalieve, an AzoneTS formulation of triamcinolone acetonide that has completed Phase III clinical trials for the treatment of corticosteroid-responsive dermatoses. It has a licensing agreement with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude SkinPrep system for skin preparation prior to the application of topical anesthetics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community; a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell Symphony for continuous glucose monitoring for use by medical facilities and/or individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd. The company was founded in 1989 and is headquartered in Iselin, New Jersey.

28 Employees
Last Reported Date: 03/28/14
Founded in 1989

echo therapeutics inc (XS5A) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

echo therapeutics inc (XS5A) Key Developments

Echo Therapeutics, Inc. Achieves Wireless Mobile Communication Milestone

Echo Therapeutics, Inc. announced that it has achieved its wireless mobile communication milestone, making it now possible for its continuous glucose sensor to transmit data to any mobile platform. This achievement marks the first key step in the strategic transformation of the Company's technology from a hospital-based medical system to a consumer product in both the wearable-health and diabetes segments. Echo's Research & Development team created a new architecture to communicate wirelessly to mobile devices, including smartphones, using Bluetooth Low Energy (BLE) connectivity, keeping power consumption and cost to a minimum. Echo also developed a mobile application to demonstrate the transmitted glucose information on a smartphone. This new system leverages the progress made recently in both the skin preparation and glucose sensing technology and is currently being evaluated using in-house clinical feasibility studies. The company received Institutional Review Board (IRB) approval for the clinical trial protocol and has commenced testing of these advancements.

Echo Therapeutics, Inc. - Special Call

To introduce its new management team; and to discuss its corporate strategy and short- and intermediate-term milestones

Echo Therapeutics, Inc. Engages BDO USA, LLP as Independent Registered Public Accounting Firm

On February 5, 2015, Echo Therapeutics, Inc. engaged BDO USA, LLP as its independent registered public accounting firm.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XS5A:GR €1.96 EUR -0.267

XS5A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.67 USD -0.66
Bayer AG €141.75 EUR +2.39
Johnson & Johnson $98.89 USD -1.71
Roche Holding AG SFr.267.40 CHF -0.70
View Industry Companies
 

Industry Analysis

XS5A

Industry Average

Valuation XS5A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,754.1x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,663.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECHO THERAPEUTICS INC, please visit www.echotx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.